PROGRAMSA program built
around a research question.
The company’s stated direction is EGFR degradation for solid tumors. Public program information is presented with its source and date.
PUBLIC PIPELINE RECORDDPI-503
Cancer · Dvant Pharma, Inc.
Preclinical · reported December 2025PreclinicalReported in source
Phase 1Not reported in source
Phase 2Not reported in source
Phase 3Not reported in source
The University of Michigan’s December 2025 pipeline lists DPI-503 under Dvant Pharma for cancer and places it in the preclinical column. That dated listing does not confirm the program’s status today.
The report does not specify a molecular structure, a particular tumor indication, clinical results, or a link between DPI-503 and a named EGFR-degradation mechanism. Those details are not inferred here.
Source: University of Michigan · drug pipeline, page 3 ↗
DEVELOPMENT CONTEXTWhat preclinical
does—and does not—mean.
Preclinical research can include laboratory and animal studies before clinical testing. It does not establish that a candidate is safe or effective in humans.
01Biological evidence
Explore how an investigational compound affects a target and relevant experimental systems.
02Safety questions
Evaluate risks, exposure, and other nonclinical considerations before a decision about human studies.
03Further development
Clinical testing and any marketing authorization are separate steps. No such milestone is announced by this page.
Source: FDA · the drug development process ↗
FOR SCIENTIFIC PARTNERSStart with the
nonconfidential context.
For current program information, scientific fit, and potential diligence, contact the company. Any confidential data exchange would require an appropriate agreement.
SCIENTIFIC & STRATEGIC PARTNERSHIPSMove the science
forward. Together.
Start a nonconfidential conversation with Dvant Pharma.
Connect with Dvant ↗